Evidence · Systematic review or meta-analysis
Role of vasopressin and terlipressin in refractory shock compared to conventional therapy in the neonatal and pediatric population: a systematic review, meta-analysis, and trial sequential analysis.
- Cardiovascular
- Medical
- Shock and hypotension
This paper is from 2017, more than five years ago. Newer evidence may have been published since.
Summary
This systematic review, meta-analysis and trial sequential analysis assessed adding vasopressin or terlipressin to conventional therapy for refractory shock of any cause in neonates and children aged 0 to 18 years. It included three randomised trials and five before-and-after studies, involving 224 patients. Pooled analyses found no association with mortality, intensive care length of stay or tissue ischaemia, although the authors suggest a possible increased risk of ischaemic events. They conclude that larger studies are needed before benefit can be established.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.